Many clinicians will be aware of the challenges faced in optimizing the treatment of patients with congenital adrenal hyperplasia (CAH) using conventional hydrocortisone, despite the availability of short-, intermediate- and long-acting formulations.

Verma and colleagues conducted an open-label phase 2 study on a new modified-release formulation of hydrocortisone which more closely mimics normal physiological patterns of serum cortisol levels. The indications are that this formulation could be highly useful in CAH patients. Verma et al., Clinical Endocrinology.

Read the full article at DOI: 10.1111/j.1365-2265.2009.03636.x